Fusion Antibodies obtains funding from Invest Northern Ireland

| By | Investments, R&D
0
76

Fusion Antibodies, a contract research organisation providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications, received a selective financial assistance letter (SFA) from Invest Northern Ireland (Invest NI) setting out the terms by which the company is entitled to grants from Invest NI totalling up to $283000, which will be used to create up to 28 additional jobs and support additional business development over the next 24 months.

Invest NI is the regional business development agency for Northern Ireland, providing support to local businesses in the region and has been a long-standing supporter to Fusion Antibodies, as well as a substantial shareholder.

Fusion is a Belfast based, revenue generating and profitable contract research organisation providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion’s proprietary CDRx™ platform and the production of antibody generating stable cell lines to provide material for use in clinical trials.

Since 2012, Fusion Antibodies has successfully sequenced over 250 antibodies and successfully completed over 100 humanisation projects for its international, blue-chip client base, which includes eight of the top 10 global pharmaceutical companies by revenue.

The company was established in 2001 as a spin out from Queen’s University Belfast. It was initially a drug development business but revised its operations to focus on CRO work in 2011.

SOURCE: fusion antibodies
SHARE
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.